secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001104659-23-023484
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q4 revenue $988M (-11% YoY), full year net loss $74M; guides FY2023 revenue $4.28-4.4B
--------------------------------------------------------------------------------

- Q4 revenue $988M (-11% reported, -6% CER); Pet Health $423M (-14%), Farm Animal $552M (-9%).
- Q4 reported net loss $54M ($0.11 loss per share); adjusted net income $95M, adjusted EPS $0.19.
- Full year 2022 revenue $4,418M (-7% reported); reported net loss $74M; adjusted EBITDA $1,023M (23.2% margin).
- FY2023 guidance: revenue $4,280-4,400M; adjusted EBITDA $920-1,000M; adjusted EPS $0.74-0.83.
- Initiated JAK inhibitor submission to FDA; received FDA approval for Bexacat (feline diabetes); EPA approval for Advantage/K9 Advantix relaunch; Bovaer launch expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/0001104659-23-023484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/tm237362d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-023484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer